Kub5-Hera RPRD1B deficiency promotes "BRCAness" and vulnerability to PARP inhibition in BRCA-proficient Breast Cancers.

CONCLUSIONS: Cancer cells with low K-H expression may have exploitable BRCAness properties that greatly expands use of PARP inhibitors beyond BRCA mutations. Our results suggest that aberrant K-H alterations may have vital translational implications in cellular responses/survival to DNA damage, carcinogenesis and personalized medicine.
PMID: 30108102 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 14, 2018 Category: Cancer & Oncology Authors: Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA Tags: Clin Cancer Res Source Type: research